<DOC>
	<DOC>NCT02191332</DOC>
	<brief_summary>Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).</brief_summary>
	<brief_title>Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Adult male or female patients with HIV type 1 infection Counterindications according to summary of product characteristics (SPC) for Viramune tablets No persons under 18 Pregnancy and breastfeeding Use of oral contraceptives Use of drugs affecting CYP450 3A metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>